RhumbLine Advisers’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

RhumbLine Advisers’s Portfolio MLNT Stock Details MLNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-8,826	Closed	-$35K	–	2966
2018 Q4	$35K	Buy	8,826 +3,280	+59%	+$41.9K	﹤0.01%	2963
2018 Q3	$110K	Buy	5,546 +1,605	+41%	+$40.6K	﹤0.01%	2853
2018 Q2	$125K	Buy	3,941 +1,426	+57%	+$51.3K	﹤0.01%	2846
2018 Q1	$93K	Buy	2,515 +478	+23%	+$31.4K	﹤0.01%	2749
2017 Q4	$161K	Buy	+2,037	New	+$151K	﹤0.01%	2689

Other funds holding MLNT

Isthmus Partners Madison, Wisconsin $953M AUM 18.74% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

ZIM

Zacks Investment Management Chicago, Illinois $12.5B AUM 29.36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

RhumbLine Advisers's MLNT Position: Q1 2019 in Review

RhumbLine Advisers sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q1 2019, closing a stake of 8,826 shares — an estimated $35K sold.

RhumbLine Advisers first reported a position in MLNT in Q4 2017 and held it in 5 quarters. The position peaked at $161K in Q4 2017. 52 funds tracked by Wall St. Rank hold MLNT as of Q1 2019.

RhumbLine Advisers reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
RhumbLine Advisers sold 8,826 Melinta Therapeutics, Inc. Common Stock shares in Q1 2019, an estimated $35K.
RhumbLine Advisers first reported a position in Melinta Therapeutics, Inc. Common Stock in Q4 2017 and held it in 5 quarters.
RhumbLine Advisers's Melinta Therapeutics, Inc. Common Stock position peaked at $161K in Q4 2017.
52 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q1 2019.

Based on RhumbLine Advisers's 13F filing for Q1 2019, filed 1 May 2019.